Cargando…
Clinical progress of nanomedicine-based RNA therapies
The clinical application of nanoparticles (NPs) to deliver RNA for therapy has progressed rapidly since the FDA approval of Onpattro® in 2018 for the treatment of polyneuropathy associated with hereditary transthyretin amyloidosis. The emergency use authorization or approval and widespread global us...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
KeAi Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897211/ https://www.ncbi.nlm.nih.gov/pubmed/35310381 http://dx.doi.org/10.1016/j.bioactmat.2021.10.018 |